Lenalidomide is an immunomodulatory agent used in oncology to support the treatment of certain blood-related cancers. It is available in 10 mg capsules and is classified as an oncology support medication. In Hong Kong, lenalidomide is a prescription-only drug regulated by the Department of Health; it is also approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Lenalidomide belongs to the class of thalidomide analogues. It exerts several actions that help control malignant cells:
These mechanisms collectively slow disease progression and improve response to other cancer therapies. The drug is absorbed after oral administration, reaching peak plasma concentrations within 2-6 hours. It is metabolized minimally and eliminated mainly unchanged in the urine.
Lenalidomide is FDA- and EMA-approved for the following adult indications, which are also recognized in Hong Kong clinical practice:
These indications reflect the drug’s role in controlling abnormal plasma-cell proliferation and improving hematologic parameters.
Evidence from clinical studies suggests potential benefit of lenalidomide in other hematologic malignancies, such as chronic lymphocytic leukemia and diffuse large B-cell lymphoma. These uses are not approved by regulatory agencies and should be considered only under strict medical supervision, after weighing individual risk-benefit profiles.
These events occur in more than 1 % of patients and are usually manageable with dose adjustments or supportive care.
Patients should seek immediate medical attention for symptoms such as unexplained bruising, severe shortness of breath, or sudden severe headache.
Because interaction data are limited, patients should inform their healthcare provider of all medications, supplements, and herbal products they are taking.
Regular follow-up with an oncologist or hematologist is essential to adjust dosing and manage adverse effects.
This article provides educational information about lenalidomide and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Lenalidomide is a newer analogue of thalidomide with greater potency and fewer side effects. It retains the anti-angiogenic and immunomodulatory actions but has a lower risk of peripheral neuropathy.
Yes, but you should carry a copy of the prescription, the REMS certification (if applicable), and a letter from your doctor confirming the medication’s necessity. Check the destination country's regulations on controlled medicines.
Maintain a regular sleep schedule, stay hydrated, and engage in light exercise as tolerated. Report persistent or worsening fatigue to your oncologist, who may adjust the dose or suggest supportive medications.
Take the missed capsule as soon as you remember on the same day, but do not take two capsules at once. If it is already near the time for the next dose, skip the missed dose and continue with your regular schedule.
Lenalidomide absorption is not significantly affected by food, although a very high-fat meal may delay peak levels. It is safe to take the capsule with meals or on an empty stomach.
Patients with moderate renal impairment can use a reduced dose (e.g., 5 mg daily). Severe impairment (creatinine clearance < 30 mL/min) generally contraindicates use unless a specialist determines a clear benefit.
Combining lenalidomide with radiation is sometimes practiced in clinical trials, but it may increase the risk of skin toxicity. Such combination should only be pursued under specialist supervision.
Severe cytopenias (especially neutropenia or thrombocytopenia), thromboembolic events, or intolerable rash are typical reasons for stopping treatment.
Weekly CBC monitoring is recommended for the first two treatment cycles, then every 2-4 weeks thereafter, or more frequently if abnormalities arise.
Lenalidomide is generally listed under the Hospital Authority’s drug formulary for approved indications, but coverage details depend on the patient’s specific subsidy scheme and clinical eligibility.
